USA flag logo/image

An Official Website of the United States Government

SBIR Phase II: Targeted Nanoparticle Delivery Agent for Treatment of Adult…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
1330140
Solicitation Year:
2013
Solicitation Topic Code:
NM
Solicitation Number:
Small Business Information
NanoValent Pharmaceuticals, Inc.
910 Technology BLVD STE G Bozeman, MT 59718-4012
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 2
Fiscal Year: 2013
Title: SBIR Phase II: Targeted Nanoparticle Delivery Agent for Treatment of Adult Leukemia
Agency: NSF
Contract: 1330140
Award Amount: $300,000.00
 

Abstract:

This Small Business Innovation Research Phase II project will develop targeted nanoparticle delivery systems capable of delivering conventional cytotoxics preferentially to tumor cells. While therapeutic nanoparticles have been introduced into clinical practice (Abraxane(TM) and Doxil(TM)) and others are in development, none have been developed that show tumor target specificity (as opposed to increased affinity) or deliver multiple therapeutic agents (whether conventional cytotoxic or targeted agents). The hypothesizias underlying this project is that targeted delivery of cancer therapy via highly modular and synthetically robust nanoparticles can improve therapeutic response while minimizing systemic toxic effects of therapy for virtually any cancer. In the Phase I study, the innovation of this approach was demonstrated by dramatically reducing the tumor burden in a transgenic mouse model of adult leukemia with our proprietary nanoparticle agents. The technical objectives in this Phase II proposal are designed to refine and optimize the nanoparticle formulation to treat adult leukemia. This Phase II proposal will enable the completion a critical phase of the preclinical studies for the nanoparticle delivery vehicle to anticipate applying for IND status for this new drug with the FDA. The broader impact/commercial potential of this project offers a great opportunity to add value to nanomaterials. The broader market for nanotech-enabled drug-delivery therapeutics was just over $1 billion in 2010 and is projected to mushroom to $136 billion by the year 2021, with a compound annual growth rate (CAGR) estimated at 49.96% over the same period. Within the U.S. alone, there are an estimated 274,930 people living with leukemia. In 2011, it is estimated that 44,600 people (25,320 men and 19,280 women) were diagnosed with leukemia, including 10 times as many adults as children and adolescents. Also in 2011, 21,780 of those already afflicted with leukemia were expected to die from the disease. The American Cancer Society projects even higher figures for 2012, estimating that 47,150 people in the U.S. will be diagnosed with leukemia and that approximately 23,540 patients will die from it. The nanoparticle delivery system proposed here is well positioned to advance the drug delivery field on a scientific level by demonstrating efficient delivery of therapeutics to leukemia cells. Combined with effective tumor delivery this technology could facilitate highly effective, ?personalized? cancer therapy that is not currently possible with routine systemic therapy.

Principal Investigator:

Jon O. Nagy
4065868420
jon.nagy@nagyconsult.com

Business Contact:

Jon O. Nagy
4065868420
jon.nagy@nagyconsult.com
Small Business Information at Submission:

NanoValent Pharmaceuticals, Inc.
910 Technology BLVD STE G Bozeman, MT 59718-4012

EIN/Tax ID: 205342640
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes